Supramolecular Nanomachines as Stimuli-Responsive Gatekeepers on Mesoporous Silica Nanoparticles for Antibiotic and Cancer Drug Delivery

Abstract

Major objectives in nanomedicine and nanotherapy include the ability to trap therapeutic molecules inside of nano-carriers, carry therapeutics to the site of the disease with no leakage, release high local concentrations of drug, release only on demand - either autonomous or external, and kill the cancer cells or an infectious organism. This review will focus on mesoporous silica nanoparticle carriers (MSN) with a large internal pore volume suitable for carrying anticancer and antibiotic drugs, and supramolecular components that function as caps that can both trap and release the drugs on-command. Caps that are especially relevant to this review are rotaxanes and pseudorotaxanes that consist of a long chain-like molecule threaded through a cyclic molecule. Under certain conditions discussed throughout this review, the cyclic molecule can be attracted to one end of the rotaxane and in the presence of a stimulus can slide to the other end. When the thread is attached near the pore opening on MSNs, the sliding cyclic molecule can block the pore when it is near the particle or open it when it slides away. The design, synthesis and operation of supramolecular systems that act as stimuli-responsive pore capping devices that trap and release molecules for therapeutic or imaging applications are discussed. Uncapping can either be irreversible because the cap comes off, or reversible when the cyclic molecule is prevented from sliding off by a steric barrier. In the latter case the amount of cargo released (the dose) can be controlled. These nanomachines act as valves. Examples of supramolecular systems stimulated by chemical signals (pH, redox, enzymes, antibodies) or by external physical signals (light, heat, magnetism, ultrasound) are presented. Many of the systems have been studied in vitro proving that they are taken up by cancer cells and release drugs and kill the cells when stimulated. Some have been studied in mouse models; after IV injection they shrink tumors or kill intracellular pathogens after stimulation. Supramolecular constructs offer fascinating, highly controllable and biologically compatible platforms for drug delivery.

Bacillus anthracis as a biological warfare agent: infection, diagnosis and countermeasures

“…For instance, Glinert and coworkers tested a protective antigen based vaccine and found that it was effective against subcutaneous spore challenge but the effi cacy was limited for systemic challenges like intravenous application of virulent strains or mutants with defi cient anthrax toxin (65). Therapies of infectious diseases can be further improved by nanoparticles serving like drug carriers, supporting material for antigen presentation during vaccination or material releasing antibiotics for a wider time span (69)(70)(71)(72)(73)(74)(75)(76). Though there are no relevant studies on anthrax, the applicability of nanoparticles in the therapy can be inferred for the future.…”

<p>Injectable Chitosan-Based Thermosensitive Hydrogel/Nanoparticle-Loaded System for Local Delivery of Vancomycin in the Treatment of Osteomyelitis</p>

“…Local therapy is rapidly developing as a promising tool for the treatment of several diseases such as tumors and osteomyelitis. 4,13 This approach can promote the availability of high concentrations of drug at the disease site and can reduce side effects. To reduce the reinfection rate of chronic osteomyelitis therapy, the drug delivery material should be biodegradable to eliminate the need to remove the material after treatment.…”

Therapeutic lipid-coated hybrid nanoparticles against bacterial infections

“…1). [29][30][31] These studies have demonstrated that antimicrobial molecules loaded into such delivery nanoparticles, either through physical encapsulation or chemical conjugation, exhibited an improved pharmacokinetic prole and therapeutic index, as compared to their free drug counterparts. Nevertheless, there are also drawbacks with delivery systems, especially those that are composed of a single material (non-hybrid), such as low drug loading efficiency, premature drug release, and rapid clearance of these nanoparticles mediated by the mononuclear phagocyte system (MPS).…”